A condition in which the myocardium is hypertrophied without an obvious cause. The hypertrophy is generally asymmetric and may be associated with obstruction of the ventricular outflow tract.
Comprehensive, easy-to-understand information about this condition
How we create this content →Connect with organizations supporting the hypertrophic cardiomyopathy community
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Connect with organizations supporting the hypertrophic cardiomyopathy community
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Connect with organizations supporting the hypertrophic cardiomyopathy community
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
European rare disease database
AI-Generated Content: This summary was generated using AI. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 2 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning hypertrophic cardiomyopathy
Updated Feb 4, 2026
A recent study highlights PRKAG2 cardiac syndrome as a rare condition that can mimic hypertrophic cardiomyopathy in adolescents. This discovery emphasizes the need for accurate diagnosis in patients presenting with unexplained cardiac hypertrophy and conduction system disease.